Cargando…
Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively regis...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643732/ https://www.ncbi.nlm.nih.gov/pubmed/29063008 http://dx.doi.org/10.1016/j.cdtm.2015.11.005 |
_version_ | 1783271597435518976 |
---|---|
author | Liu, Feng-Di Zhao, Rong Wang, Xue-Mei Wang, Shuo Shen, Xiao-Lei Tao, Xiao-Xiao Zheng, Bo Peng, Jia-Li Zhang, Hui Mo, Ran Tong, Yan Li, Wen-Ting Feng, Xiao-Yan Li, Ge-Fei Shu, Liang Liu, Jian-Ren |
author_facet | Liu, Feng-Di Zhao, Rong Wang, Xue-Mei Wang, Shuo Shen, Xiao-Lei Tao, Xiao-Xiao Zheng, Bo Peng, Jia-Li Zhang, Hui Mo, Ran Tong, Yan Li, Wen-Ting Feng, Xiao-Yan Li, Ge-Fei Shu, Liang Liu, Jian-Ren |
author_sort | Liu, Feng-Di |
collection | PubMed |
description | OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. PATIENTS: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. RESULTS: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. CONCLUSION: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance. |
format | Online Article Text |
id | pubmed-5643732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56437322017-10-23 Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai Liu, Feng-Di Zhao, Rong Wang, Xue-Mei Wang, Shuo Shen, Xiao-Lei Tao, Xiao-Xiao Zheng, Bo Peng, Jia-Li Zhang, Hui Mo, Ran Tong, Yan Li, Wen-Ting Feng, Xiao-Yan Li, Ge-Fei Shu, Liang Liu, Jian-Ren Chronic Dis Transl Med Original Article OBJECTIVE: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. PATIENTS: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. RESULTS: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. CONCLUSION: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance. KeAi Publishing 2016-01-08 /pmc/articles/PMC5643732/ /pubmed/29063008 http://dx.doi.org/10.1016/j.cdtm.2015.11.005 Text en © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Liu, Feng-Di Zhao, Rong Wang, Xue-Mei Wang, Shuo Shen, Xiao-Lei Tao, Xiao-Xiao Zheng, Bo Peng, Jia-Li Zhang, Hui Mo, Ran Tong, Yan Li, Wen-Ting Feng, Xiao-Yan Li, Ge-Fei Shu, Liang Liu, Jian-Ren Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title | Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title_full | Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title_fullStr | Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title_full_unstemmed | Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title_short | Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai |
title_sort | does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: an inpatient registration study in shanghai |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643732/ https://www.ncbi.nlm.nih.gov/pubmed/29063008 http://dx.doi.org/10.1016/j.cdtm.2015.11.005 |
work_keys_str_mv | AT liufengdi doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT zhaorong doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT wangxuemei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT wangshuo doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT shenxiaolei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT taoxiaoxiao doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT zhengbo doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT pengjiali doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT zhanghui doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT moran doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT tongyan doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT liwenting doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT fengxiaoyan doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT ligefei doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT shuliang doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT liujianren doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai |